1. Adjuvant (chemo)radiotherapy for patients with head and neck cancer: can comorbidity risk scores predict outcome?
- Author
-
Marschner SN, Maihöfer C, Späth R, Haehl E, Reitz D, Kienlechner N, Schüttrumpf L, Baumeister P, Pflugradt U, Heß J, Zitzelsberger H, Unger K, Belka C, and Walter F
- Subjects
- Humans, Middle Aged, Male, Female, Aged, Retrospective Studies, Adult, Risk Factors, Aged, 80 and over, Treatment Outcome, Risk Assessment, Carcinoma, Squamous Cell therapy, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Survival Rate, Head and Neck Neoplasms therapy, Head and Neck Neoplasms mortality, Germany, Otorhinolaryngologic Neoplasms therapy, Otorhinolaryngologic Neoplasms mortality, Otorhinolaryngologic Neoplasms pathology, Otorhinolaryngologic Neoplasms radiotherapy, Disease-Free Survival, Prognosis, Comorbidity, Chemoradiotherapy, Adjuvant
- Abstract
Purpose: This study compares the objective American Society of Anesthesiologists (ASA) and Adult Comorbidity Evaluation-27 (ACE-27) scores with the subjective Eastern Cooperative Oncology Group performance status (ECOG PS) for patient outcome prediction., Methods: We retrospectively analyzed head and neck squamous cell carcinoma patients treated with adjuvant (chemo)radiotherapy at the LMU Munich from June 2008 to June 2015. The study focused on associations between patient outcomes; treatment failures; known risk factors (including human papillomavirus [HPV] status and tumor stage); and the comorbidity indices ECOG-PS, ASA score, and ACE-27. The Kaplan-Meier method and Cox proportional hazards model were used for survival analysis and identifying independent risk factors., Results: A total of 302 patients were analyzed, 175 received concurrent chemotherapy. Median follow-up was 61.8 months, and median age at diagnosis was 61 years. The 3‑ and 5‑year overall survival (OS) and disease-free survival (DFS) rates were 70.5%/60.2% and 64.7%/57.6%, respectively. Both ACE-27 and ASA showed significant correlations with OS in univariate and multivariate analyses, while ECOG-PS was significant only in univariate analysis. ASA and ACE-27 scores were also significantly correlated with local and locoregional recurrence, but only HPV status and tumor stage were significant in multivariate models., Conclusion: ACE-27 and ASA score effectively categorize patients' risks in adjuvant radiotherapy for head and neck cancer, proving more predictive of overall survival than ECOG-PS. These results underscore the importance of objective comorbidity assessment and suggest further prospective studies., Competing Interests: Declarations. Conflict of interest: S.N. Marschner, C. Maihöfer, R. Späth, E. Haehl, D. Reitz, N. Kienlechner, L. Schüttrumpf, P. Baumeister, U. Pflugradt, J. Heß, H. Zitzelsberger, K. Unger, C. Belka, and F. Walter declare that they have no competing interests. Ethical standards: All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. A positive ethics vote (no. 448-13) of the local ethics committee (LMU Munich, Germany) was available in the context of the clinical cooperation group (KKG) “Personalized radiotherapy for head and neck tumors.” Informed consent was obtained from all individual participants included in the study. All patients are part of the adjuvant cohort of the clinical cooperation group “Personalized Radiotherapy in Head and Neck Cancer,” which was separately published by Maihöfer et al. [9]., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF